Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Update on CTCL and Emerging Therapies
Description
Gina Chung discussed recent advancements in the treatment and understanding of cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sézary syndrome. She highlighted that the prevailing theory of these conditions being skin-limited is being challenged as malignant T-cells may circulate between the skin and blood, indicating a more systemic nature. Significant new treatments have emerged, including Brentuximab, a drug for CD30-positive lymphomas, and Mogamilizumab, targeting CCR4. Both therapies show promising responses, especially in cases with blood involvement. There is growing interest in various emerging treatments, including photodynamic therapy using hypericin, antibodies targeting PD-1, and CAR T-cell therapies tailored to specific T-cell markers. Additionally, novel approaches are being explored to overcome challenges such as fratricide in CAR T therapies, where engineered T-cells inadvertently attack each other due to shared antigens. Chung emphasized the exciting potential for personalized medicine in CTCL, with ongoing trials evaluating the efficacy of new therapies based on molecular and genetic profiling.
View moreConclusions
- Mycosis Fungoides (MF) is characterized by significant heterogeneity in malignant T cells, which can exist in both skin and blood.
- Emerging evidence suggests that malignant T cells may originate from immature precursors rather than mature skin-resident memory T cells.
- CTCL is not a strictly skin-limited disease; rather, malignant T cells can circulate in the blood even in early stages of the disease.
- Effective treatments for MF and CTCL are evolving, with promising results from combined skin-directed and systemic therapies.
- Brentuximab vedotin has become a preferred option for treating CD30-positive MF, showing a significantly higher response rate compared to traditional therapies.
- Mogamulizumab has proven to be effective against CCR4-expressing T cells, with particular efficacy in patients with Sézary syndrome.
- Topical hypericin photodynamic therapy demonstrates a good response rate for early-stage CTCL and offers advantages over traditional UV phototherapy.
- New immunotherapies, including anti-PD-1 therapies and CAR T-cell therapy, are being explored and may provide targeted treatment options in the future.
- Future therapeutics may benefit from employing precision medicine approaches, guided by biomarker testing to optimize treatment strategies for individual patients.
- Hamrouni A, et al. Clin Cancer Res. 2019 May 15;25(10):3104-3114.
- Iyer A, et al. Blood. 2019 Oct 31;134(18):1517-1527.
- Khodadoust MS, et al. Blood. 2023 Feb 16;141(7):695-703.
- Prince HM, et al. Lancet. 2017 Aug 5;390(10094):555-566.
- Horwitz SM, et al. Blood Adv. 2021 Dec 14;5(23):5098-5106.
- Kim YH, et al. J Clin Oncol. 2015 Nov 10;33(32):3750-8.
- Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204.
- Afifi S, et al. Expert Opin Drug Saf. 2019 Sep;18(9):769-776.
- Fox FE, et al. J Invest Dermatol. 1998 Aug;111(2):327-32.
- Kim EJ, et al. JAMA Dermatol. 2022 Sep 1;158(9):1031-1039.
- Khodadoust M, et al. J Clin Oncol. 2020 Jan 1;38(1):20-28.
- Beygi S, et al. Blood Adv. 2021 Feb 9;5(3):771-774.
- Bagot M, et al. Lancet Oncol. 2019 Aug;20(8):1160-1170.
- Bazewicz C, et al. Oncologist. 2024 Jan 18:oyad345.
- Moskowitz AJ, et al. Blood. 2021 Dec 30;138(26):2828-2837.
- Trum NA, et al. Haematologica. 2022 Mar 1;107(3):702-714.
- Caforio M, et al. Cancers. 2021; 13(16):4040.
- Maciocia PM, et al. Nat Med. 2017;23(12):1416-1423.